Targeting Plasma Cells in Autoimmune Diseases

Antibodies specific for self-antigens mediate life-threatening pathology in several autoimmune diseases. Clearly the ability to target the plasma cells (PCs) producing the autoantibodies would be of great clinical benefit. Current immunosuppressive therapies are based on the premise that autoreactiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Tarlinton, David M., Hodgkin, Philip D.
Formato: Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2004
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2211780/
https://www.ncbi.nlm.nih.gov/pubmed/15173204
http://dx.doi.org/10.1084/jem.20040719
_version_ 1782148552507523072
author Tarlinton, David M.
Hodgkin, Philip D.
author_facet Tarlinton, David M.
Hodgkin, Philip D.
author_sort Tarlinton, David M.
collection PubMed
description Antibodies specific for self-antigens mediate life-threatening pathology in several autoimmune diseases. Clearly the ability to target the plasma cells (PCs) producing the autoantibodies would be of great clinical benefit. Current immunosuppressive therapies are based on the premise that autoreactive PCs are short-lived and replenished from ongoing immune responses. However, recent results question this assumption and suggest that optimizing the treatment of severe autoimmune conditions will require a significant investment in elucidating the details of PC biology.
format Text
id pubmed-2211780
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-22117802008-03-11 Targeting Plasma Cells in Autoimmune Diseases Tarlinton, David M. Hodgkin, Philip D. J Exp Med Commentary Antibodies specific for self-antigens mediate life-threatening pathology in several autoimmune diseases. Clearly the ability to target the plasma cells (PCs) producing the autoantibodies would be of great clinical benefit. Current immunosuppressive therapies are based on the premise that autoreactive PCs are short-lived and replenished from ongoing immune responses. However, recent results question this assumption and suggest that optimizing the treatment of severe autoimmune conditions will require a significant investment in elucidating the details of PC biology. The Rockefeller University Press 2004-06-07 /pmc/articles/PMC2211780/ /pubmed/15173204 http://dx.doi.org/10.1084/jem.20040719 Text en Copyright © 2004, The Rockefeller University Press This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle Commentary
Tarlinton, David M.
Hodgkin, Philip D.
Targeting Plasma Cells in Autoimmune Diseases
title Targeting Plasma Cells in Autoimmune Diseases
title_full Targeting Plasma Cells in Autoimmune Diseases
title_fullStr Targeting Plasma Cells in Autoimmune Diseases
title_full_unstemmed Targeting Plasma Cells in Autoimmune Diseases
title_short Targeting Plasma Cells in Autoimmune Diseases
title_sort targeting plasma cells in autoimmune diseases
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2211780/
https://www.ncbi.nlm.nih.gov/pubmed/15173204
http://dx.doi.org/10.1084/jem.20040719
work_keys_str_mv AT tarlintondavidm targetingplasmacellsinautoimmunediseases
AT hodgkinphilipd targetingplasmacellsinautoimmunediseases

Ejemplares similares